Latest news with #OrganOx
Yahoo
13-05-2025
- Business
- Yahoo
TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher?
After a depressing 2024, TransMedics Group stock is surging in 2025. Management recently raised its sales outlook for 2025. TransMedics isn't the only company with a warm perfusion device for storing and transporting organs. 10 stocks we like better than TransMedics Group › Shares of TransMedics Group (NASDAQ: TMDX) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance revisions and unwanted attention from short-sellers pushed the stock down late last year, but things are looking up. From the end of 2024 through the opening bell on Monday, May 12, TransMedics stock soared about 81%, and investors want to know if it can keep climbing. To find out if TransMedics is a good growth stock to buy now, we'll need to weigh the reasons it soared against some of the challenges it faces. In a nutshell, TransMedics stock began 2025 in a somewhat depressed state due to a revenue growth slowdown. Annual revenue soared 83% in 2024, but a scathing short report in January caused investors to question its ability to continue growing so quickly. Then management signaled a severe slowdown this February when it predicted revenue growth of just 20% to 25% this year. TransMedics markets an organ care system (OCS) that pumps donated hearts, lungs, and livers with warm blood. This is a huge improvement over the current standard, which is basically a cooler full of ice. TransMedics' OCS is the only device approved by the Food and Drug Administration (FDA) to transport multiple organs, but it isn't the only warm perfusion device on the market. In 2021, the FDA approved the OrganOx Metra to pump warm blood through donated livers. This could be a big competitive threat because liver transplantation is responsible for 76% of total revenue at TransMedics. Since February, privately held OrganOx has raised $160 million to accelerate the growth of its device in the limited market for donated organ transportation. Luckily for TransMedics shareholders, first-quarter results suggest OrganOx isn't the serious threat it could be. First-quarter liver revenue soared 62% year over year, or 22% higher than the previous three-month period. Perhaps encouraged by the lack of competition for liver sales from OrganOx, TransMedics management raised guidance for total revenue this year to a range between $565 million and $585 million. The revised guidance implies a 30% gain at the midpoint of the provided range. During the two-year period that ended last December, total heart, lung, and liver transplants in the U.S. rose by 20% to 17,792. TransMedics is responsible for nearly all that growth. Completed transplants that didn't involve TransMedics rose by just 2% over the same time frame. There are over 103,000 Americans on the national transplant waiting list, according to the U.S. Department of Health and Human Services. Unfortunately for TransMedics, 89,792 are waiting for kidneys. Since we're born with two, we tend to donate them at convenient times. As a result, kidneys usually don't require transportation and storage services. While an expansion to include kidneys isn't likely to provide a huge boost for TransMedics, gaining market share for hearts, lungs, and livers could allow it to continue growing sales at more than 20% annually for several more years. The company's share of these three organs rose to 21% in 2024 from just 7% in 2022. TransMedics stock has been trading for 8.5 times its trailing-12-month sales. This is a high valuation for a medical device company, but not if we assume it can keep growing overall sales by roughly 20% annually in the decade ahead. Strong growth of liver revenue in the first quarter suggests OrganOx isn't a fierce competitor yet. That said, the privately held company hasn't had much time to put its new sources of capital to work. Instead of buying now or adding to a position, it's probably a good idea to wait another quarter to make sure TransMedics can continue growing its share of liver transplants despite well-funded competition. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $614,911!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $714,958!* Now, it's worth noting Stock Advisor's total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Cory Renauer has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy. TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-05-2025
- Business
- Associated Press
OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
OXFORD, England and MADISON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. Together with the first closing of its private placement on February 24, 2025, OrganOx raised $160 million in primary and secondary equity financing to accelerate growth opportunities for its metra ® platform technology in the large and high growth organ technology global market. Approved in the U.S., Europe, Canada, and Australia, the OrganOx metra ® is a normothermic machine perfusion (NMP) platform technology utilized in over 5,000 liver transplants to date. The metra ® keeps donor livers in a metabolically active state outside the body, providing transplant teams with the opportunity for functional assessment of the organ prior to transplant which leads to an increased number of organs available for transplant, while also extending liver preservation times as compared to static cold storage. The company is also expanding its metra ® technology for kidney transplants, currently in development, and in collaboration with eGenesis, recently gained FDA clearance to begin a first-in-human clinical study of the use of its metra ® technology combined with eGenesis' genetically engineered porcine livers to support patients with acute-on-chronic liver failure. 'It is an honor and a privilege to have Intuitive Ventures and Terumo Ventures invest in OrganOx,' said Oern R. Stuge, MD, MBA, Executive Chairman at OrganOx. 'Our board and management team look forward to working together with these industry leaders to further advance our organ technologies that save patient lives.' Piper Sandler acted as exclusive financial advisor and Latham & Watkins acted as legal counsel to OrganOx in this transaction. About OrganOx OrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra ® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 5,000 liver transplants to date to keep donor livers in a metabolically active state outside the body enabling longer preservation times and functional assessment of the organ prior to transplant, leading to an increased number of organs available for transplant. Learn more at About Intuitive Ventures Intuitive Ventures invests in companies reimagining the future of minimally invasive care. Our global focus spans diagnostics, MedTech, therapies, and digital health. With $250 million in assets under management, we back teams that share our passion for advancing positive patient outcomes, improving provider experience, and increasing the efficiency of healthcare delivery. Intuitive Ventures' experience as operators and clinicians combined with unique access to Intuitive Surgical's technical and commercial reach enables our portfolio companies to revolutionize the delivery of patient care. More information and future updates can be found at: About Terumo Ventures Terumo Ventures was founded as a corporate venture capital fund to drive Terumo's growth through strategic funding. Terumo Ventures invest in companies providing innovative solutions that achieve Terumo's Group Mission: 'Contributing to Society through Healthcare.' More information and future updates can be found at: Contacts OrganOx Investor Relations: Steve Deitsch Chief Financial Officer, OrganOx [email protected] OrganOx Media: Emma Yang Health+Commerce [email protected]
Yahoo
16-04-2025
- Business
- Yahoo
FDA clears eGenesis' genetically engineered porcine liver for Phase I trial
eGenesis has gained US Food and Drug Administration (FDA) clearance on an investigational new drug (IND) application for a genetically engineered porcine (pig) liver. The organ is designed for use with OrganOx's extracorporeal liver cross-circulation (ELC) system for patients with acute-on-chronic liver failure (ACLF). The biotech and medtech companies entered an exclusive clinical co-development agreement last year to advance their respective technologies in combination. Research indicates that around 35,000 patients in the US are hospitalised for ACLF each year. Meanwhile, most individuals wait between three and five years for a kidney, as per the American Kidney Fund. eGenesis' pig liver is intended to draw down on the mortality rates in patients awaiting a transplant. The Phase I trial plans to enrol 20 patients with ACLF (Grade 2 to Grade 3) and hepatic encephalopathy (≤ Grade 3), who are ineligible for transplant, across multiple US centres. eGenesis' EGEN-5784 pig liver in combination with OrganOx's ELC is intended to support the function of patients' decompensated liver, potentially allowing for the recovery of a patient's native liver or providing sufficient time to receive a liver transplant. eGenesis CEO Michael Curtis commented: 'The FDA's clearance of EGEN-5784 in combination with the OrganOx ELC system represents a significant advance towards fulfilling our mission to develop safe and effective human-compatible organs that have the potential to transform the treatment of organ failure and extend patients' lives. Last year, OrganOx and eGenesis completed their first extracorporeal perfusion of a research donor using their combined offerings. The process involved circulating a recently deceased donor's blood through the genetically engineered EGEN-5784 pig liver outside of their body, with the donor being the first to be enrolled in the companies' ongoing PERFUSE-2 study. In the first procedure, stable blood flow, pressure, and pH were maintained throughout the procedure, with no evidence of rejection observed, with the perfusion electively stopped, per-protocol, at 72 hours, with the liver appearing healthy. Last year, eGenesis became the first company to successfully implant a pig kidney into a living patient at Massachusetts General Hospital (MGH) under the FDA's expanded access programme and concluded a $191m Series D financing round to continue the development of EGEN-5784. While Rick Slayman, the end-stage kidney disease patient who received the implant, died two months later, MGH stated there was no indication that the death was a result of the transplant. "FDA clears eGenesis' genetically engineered porcine liver for Phase I trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
NBC News
15-04-2025
- Health
- NBC News
FDA OKs trial of pig livers as dialysis-like treatment for liver failure
U.S. researchers will soon test whether livers from a gene-edited pig could treat people with sudden liver failure — by temporarily filtering their blood so their own organ can rest and maybe heal. The first-of-its-kind clinical trial has been cleared by the Food and Drug Administration, according to pig producer eGenesis, which announced the step Tuesday with its partner OrganOx. An estimated 35,000 people in the U.S. are hospitalized each year when their liver suddenly fails. There are few treatment options and death rates as high as 50%. Many don't qualify for a liver transplant or can't get a match in time. The new study, which is expected to get underway later this spring, is a twist on the quest for animal-to-human organ transplants. Researchers won't transplant the pig liver but instead will attach it externally to study participants. The liver is the only organ that can regenerate, but the question is whether having the pig's liver filter the patient's blood for several days could give it that chance. In experiments with four deceased bodies, that 'bridge' attempt showed the pig liver could support some functions of a human liver for two or three days, said Mike Curtis, CEO of Massachusetts-based eGenesis, which genetically modifies pigs so their organs are more humanlike. The trial will enroll up to 20 patients in intensive-care units who don't qualify a liver transplant, he said. A device made by Britain's OrganOx, currently used to preserve donated human livers, will pump participants' blood through the pig liver. It's the latest step in attempts to use gene-edited pig organs to save human lives. Pig kidneys from eGenesis and another pig producer, United Therapeutics, are being used in experimental transplants.
Boston Globe
15-04-2025
- Health
- Boston Globe
FDA OKs trial of pig livers as dialysis-like treatment for liver failure
The new study, which is expected to get underway later this spring, is a twist on the quest for animal-to-human organ transplants. Researchers won't transplant the pig liver but instead will attach it externally to study participants. Advertisement The liver is the only organ that can regenerate, but the question is whether having the pig's liver filter the patient's blood for several days could give it that chance. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In experiments with four deceased bodies, that 'bridge' attempt showed the pig liver could support some functions of a human liver for two or three days, said Mike Curtis, CEO of Massachusetts-based eGenesis, which genetically modifies pigs so their organs are more humanlike. The trial will enroll up to 20 patients in intensive-care units who don't qualify a liver transplant, he said. A device made by Britain's OrganOx, currently used to preserve donated human livers, will pump participants' blood through the pig liver. It's the latest step in attempts to use gene-edited pig organs to save human lives. Pig kidneys from eGenesis and another pig producer, United Therapeutics, are being used in experimental transplants. Advertisement The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
